5月20日连板股分析：连板股晋级率34% 高位股大面积退潮 | | 九鼎投资 (创投) | | --- | --- | | 其他涨停 | 苏州龙杰8天6板（纺织+军工） | 今日共77股涨停，连板股总数28只，其中三连板及以上个股8只，上一交易日共23只连板股，连板股晋级率34.78%（不含ST股、退市股）。个股方面，全市 场超3800只个股上涨，连续第二个交易日逾百股涨超9%，小盘股备受青睐，北证50、微盘股指数均创历史新高。高位股开始退潮，利君股份、渝三峡A、 红墙股份、尤夫股份等人气股跌停，成飞集成断板，市场连板高度被压缩至4板。板块方面，以谷子经济、宠物经济、医美为代表的新消费板块全天表现强 势，其中郑中设计、丽人丽妆4连板，拉芳家化6天4板，天元宠物20CM2连板；并购重组概念依旧受到热捧，综艺股份5天4板，天汽模3连板，北交所五新 隧装30CM2连板。 | 连板数 | 晋级率 | | 2025-5-20 | | --- | --- | --- | --- | | 3 #4 | 2/2=100% | 郑中设计(城市更新+IP经济) | | | | | 天汽模(并购重组) | | | 2进3 | 6/ ...

Group 1 - The article discusses the challenges faced by the hyaluronic acid (HA) industry, claiming it has been misrepresented and undermined in recent years due to misleading narratives in the capital market [2][6] - Huaxi Biological specifically names several securities firms and their reports that have contributed to the negative perception of HA, including Huatai Securities and Anxin Securities [2][5][7] - The company argues that the rise of the "outdated" narrative surrounding HA is a result of a capital market phenomenon that seeks to shift focus to new investment themes, thereby undermining established industries [6][8] Group 2 - Huaxi Biological highlights the significant growth of competitor Juzhi Biological, which reported a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.07%, and a net profit of 2.062 billion yuan, up 42.06% [5][10] - The company emphasizes its own historical performance, noting that from 2018 to 2022, it experienced substantial revenue and profit growth, with annual revenue growth rates exceeding 87% and net profit growth rates surpassing 90% [10] - However, Huaxi Biological has faced a sharp decline in performance recently, with a projected revenue of 5.371 billion yuan and a net profit of 174 million yuan in 2024, representing year-on-year decreases of 11.61% and 70.59% respectively [10][11] Group 3 - The company is undergoing significant internal reforms, described as a "bone-scraping" process, initiated by the chairman to address management issues and improve operational efficiency [10][11] - The article indicates that Huaxi Biological is currently facing both internal challenges due to its restructuring efforts and external pressures from competition in the market [11]

针对突然向券商"开炮"，A股医美巨头华熙生物（688363.SH，股价53.21元，市值256.3亿元）作出最新 回应。 今日（5月20日）午间，华熙生物方面向《每日经济新闻》记者发来独家回应。在回应中，华熙生物表 示："透明质酸是中国在全球占据第一份额的优势产业，涉及到科研、医疗、医美、美妆、营养健康等 多个生命健康的相关领域，因此整个透明质酸产业都一直希望华熙生物作为行业龙头可以带头发声，纠 正近年来针对透明质酸这一生命科学关键物质的罔顾科学的踩踏和抹黑。" 5月19日晚间，华熙生物在其官方微信号发布《概念总在重演，科技永远向前》的文章，对市场上流行 的"玻尿酸过时"的观点，进行了点名驳斥。 《每日经济新闻》记者注意到，华熙生物在文章中点名几家券商机构称，2022年开始，随着资本市场不 断追求新的公司题材，重组胶原蛋白概念被看似幸运地选中了。为了营造比透明质酸产业更大的预期， 围绕某重组胶原企业的研报中，出现了大量直接针对中国透明质酸产业的所谓"对比研究"。 文章称，透明质酸"过时论"的兴起，本质上是一场由"浮躁资本"构建的题材幻象，试图用"神话过时"绕 开中国产业发展必然面临的进阶过程，引导资本和市场资 ...

Group 1: Industry Initiatives - The China Fragrance and Cosmetic Industry Association and the China Association of Plastic Surgery jointly released a health ecosystem initiative for the medical beauty and cosmetics industry, emphasizing the importance of scientific rigor and rational guidance in product efficacy [1] - The initiative calls for promoting public understanding through scientific education and collaboration with authoritative institutions to enhance public awareness of technological paths [1] - It advocates for innovation and diversity in the industry, encouraging cooperation in ingredient innovation, formula optimization, and process breakthroughs [1] - The initiative stresses the need for civilized marketing and honest promotion, aiming to establish objective and fair marketing practices as industry norms [1] - It proposes the establishment of an industry self-discipline system and a self-discipline alliance to evaluate and publicly disclose results of any misleading or uncivil behavior [1] Group 2: Company Positioning - Huaxi Biological published an article addressing misleading conclusions regarding the comparison between collagen and hyaluronic acid, which have been widely circulated in the media [2] - The company clarified that its concerns about collagen products primarily relate to the exaggerated claims of topical collagen skincare products, emphasizing that effective collagen products require injection [2][3] - Huaxi Biological's strategy focuses on leveraging hyaluronic acid to develop synthetic biological capabilities, exploring effective substances in life sciences, while maintaining a unified strategic logic [3] - The company has not promoted collagen as a mainstream technology in consumer products due to insufficient scientific evidence supporting its efficacy in managing aging compared to hyaluronic acid [3] - Huaxi Biological believes that the extracellular matrix (ECM) is the comprehensive research and industrial transformation direction that includes all key substances like hyaluronic acid, collagen, and elastin [3]

5月20日，港股消费板块早盘震荡攀升，相关热门ETF中，港股消费ETF（513230）现涨近1.5%。持仓股中，零跑汽车领涨超4%，小米集团、新秀丽均 跟涨超3%，巨子生物、思摩尔国际、阿里巴巴等涨幅居前。港股消费ETF（513230）近期回暖趋势较为清晰，已连续3个交易日获资金净流入，持续受资金 青睐。 消息面上，2025年全国精品首发季暨"首发上海"系列活动日前正式在上海启动，邀请全球游客打卡首店、观赏首展、欣赏首秀，实地感受中国和上海消 费市场的巨大魅力。上海还同步发布了"首发上海3.0"政策，将试点首发进口消费品检验便利化措施和首发进口化妆品快速通关模式，进一步优化全球新品 的首发环境。据悉，商务部将组织各地开展丰富多彩、各具特色的精品首发活动，激发消费新动能，持续释放消费潜力。同时，将加大对首发经济的支持力 度，发挥好重点展会作用。 开源证券认为， 消费复苏主旋律下，关注契合"情绪消费"主题且品牌势能和竞争力边际提升的龙头公司，重点关注四条投资主线。（1）黄金珠宝：关 注具备差异化产品力和消费者深度洞察力的黄金珠宝品牌；（2）线下零售：关注顺应趋势积极变革探索的零售企业（超市、百货、连锁）；（3）化 ...

Group 1 - The Hong Kong stock market experienced a collective rise, with the Consumer Theme Index increasing by 0.74% as of May 20 [1] - The Hong Kong Consumer ETF (159735) rose by 1.1% with a turnover rate of 2.25%, driven by significant gains in stocks such as Li Auto and Xiaomi [1] - In April, the total retail sales of consumer goods reached 37,174 billion yuan, marking a year-on-year growth of 5.1%, while retail sales excluding automobiles grew by 5.6% [1] Group 2 - Open Source Securities emphasizes the importance of "emotional consumption" and suggests focusing on leading companies with enhanced brand power and competitiveness [2] - Four investment themes are highlighted: (1) Gold and jewelry brands with differentiated product offerings; (2) Retail enterprises adapting to trends; (3) High-quality domestic beauty brands in growing segments; (4) Medical aesthetics companies with unique product lines [2]

Group 1 - The annual "618" shopping festival has begun, with over 13,000 brands achieving doubled sales in the first hour of Tmall's event [1][2] - The beauty and personal care sector has shown remarkable performance in the A-share market, driven by consumption recovery policies and the "618" promotion [1][3] - Analysts suggest that the beauty sector will see structural opportunities due to the "618" event, with a focus on high-quality companies in segments like gold jewelry, medical beauty, offline retail, and pet products [1][4] Group 2 - E-commerce platforms have started their "618" promotions earlier this year, extending the overall duration of the event [2] - Tmall reported that 43 brands achieved over 100 million yuan in sales within the first hour, a more than 50% increase compared to last year [2] - The beauty sector's GMV during the pre-sale period reached between 2.5 billion to 3.5 billion yuan, showing positive year-on-year growth [2] Group 3 - The "618" event has simplified consumer decision-making, enhancing the shopping experience and contributing significantly to brand revenues [3] - The beauty care sector has seen a 4.07% increase in stock prices over the last five trading days, leading among 31 sectors [3] - Analysts recommend focusing on high-growth segments such as gold jewelry, innovative offline retail, and differentiated medical beauty products for investment opportunities [4] Group 4 - The pet economy is gaining attention, with domestic brands benefiting from product innovation and refined marketing strategies [4] - The growth of the pet economy is supported by favorable trends in pet food exports, indicating a positive outlook for related businesses [4]

（原标题：医美市场规模有望增至6000亿！今年已注册1.41万家相关企业） 2.医美相关企业均匀分布在二三线、新一线城市 企查查数据显示，从城市能级分布来看，医美相关现存企业分布较均匀，其中分布在三线城市的医美相 关企业最多，占比22.56%。其次，分布在二线城市、新一线城市的相关企业分别占比21.23%、 20.39%。 3.归属于居民服务、修理和其他服务业的相关企业最多 企查查数据显示，从国标行业来看，归属于居民服务、修理和其他服务业的医美相关企业最多，占比 34.06%。其次，归属于卫生和社会工作的相关企业占比23.14%。此外，医美相关企业也广泛分布在批 发和零售业、租赁和商务服务业、科学研究和技术服务业等国标行业。 近年来，随着社交媒体的普及，美貌得以展现，人们对美的追求愈发多元化。加之政策扶持医美行业规 范化发展与人民可支配收入的提升，美妆、医美等"颜值经济"呈爆发式增长。有业内人士认为，从长期 来看，医美行业依然处于快速成长期，具有巨大的拓展空间。据弗若斯特沙利文预测，到2026年，我国 医美市场规模将达到3998亿元，到2030年有望增至6382亿元，年复合增长率为12.4%。 企查查数据显示 ...

对玻尿酸（透明质酸）、重组胶原蛋白两种流行医美原料的比较，引发了医美巨头华熙生物(688363)对 多家券商研报的公开"声讨"。 深夜发文"声讨" 5月17日晚23时许，华熙生物官方微信号发文《概念总在重演，科技永远向前》，将矛头指向多家券商 研报，相关研报提出胶原蛋白在皮肤修复、抗衰老和副作用等方面强于玻尿酸。 华熙生物在微信文章中表示，2022年开始，随着资本市场不断追求新的公司题材，重组胶原蛋白概念被 看似幸运地选中了。为了营造比透明质酸产业更大的预期，围绕某重组胶原企业的研报中，出现了大量 直接针对中国透明质酸产业的所谓"对比研究"。 包括华泰证券、安信证券等多家券商研报被华熙生物节选发在了上述文章中。华熙生物文章称，这些误 导性"结论"伴随着随后兴起的"玻尿酸过时论"被媒体和自媒体红人广泛传播，形成了资本市场与消费市 场的舆论共振，伤害了经几代人努力的、一个中国优势产业的市场转化基础。 华熙生物表示，透明质酸这一成分及相关产业在近几年资本市场的概念切换中遭遇了谎言与践踏，被描 述为"过时""不如某物质安全""不如某物质更具生物活性""不如某物质具备市场价值"……这些抹黑与受 操控的自媒体及网络上的虚 ...

Core Viewpoint - The article published by Huaxi Biological refutes the notion that hyaluronic acid is "outdated," arguing that this perspective is a product of "impatient capital" attempting to divert attention from the necessary evolution of China's industry [1][2]. Group 1: Industry Analysis - The rise of the "hyaluronic acid is outdated" theory is characterized as a mirage created by certain capital forces, aiming to shift focus towards new investment themes and companies [2]. - Huaxi Biological directly names several brokerage research reports, including those from Western Securities, which have contributed to the spread of misleading comparisons against the hyaluronic acid industry [2][3]. - The misleading conclusions associated with the "hyaluronic acid is outdated" narrative have been widely disseminated by media and influencers, damaging the market foundation of a competitive Chinese industry [3]. Group 2: Company Performance - Huaxi Biological's stock, once reaching a peak of 309.43 yuan per share, has been on a downward trend since July 2021, closing at 50.6 yuan per share on May 19, with a slight increase of 0.22% [3]. - The company staff indicated that stock price fluctuations are influenced by a combination of factors, and they have not yet experienced any legal disputes related to the article [3].